🏢CompaniesAstraZeneca Gains Dual US and European Approvals for Rare Disease and Oncology Treatments
AstraZeneca shares rose 0.73% to $185.78 in premarket trading after securing major regulatory clearances in the US and EU for its rare disease drug Klygefa and an oncolog…